Anti-PHF-tau antibodies and their uses
The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
1. An isolated antibody that binds paired helical filament tau (PHF-tau) comprising a heavy chain complementarity determining region (HCDR) 1, a heavy chain complementarity determining region (HCDR) 2 and a heavy chain complementarity determining region (HCDR) 3 of a heavy chain variable region (VH) of SEQ ID NO: 37, and a light chain complementarity determining region (LCDR) 1, a light chain complementarity determining region (LCDR) 2 and a light chain complementarity determining region (LCDR) 3 of a light chain variable region (VL) of SEQ ID NO: 38.
2. The isolated antibody of claim 1 , wherein the HCDR1, the HCDR2 and the HCDR3 comprise amino acid sequences of SEQ ID NOs:25, 26 and 27, respectively, and the LCDR1, the LCDR2 and the LCDR3 comprise amino acid sequences of SEQ ID NOs: 28, 29 and 30, respectively.
3. The isolated antibody of claim 1 , wherein the antibody is humanized.
4. The isolated antibody of claim 2 , wherein the antibody is humanized.
5. An isolated polynucleotide encoding an antibody heavy chain comprising a VH of comprising SEQ ID NOs: 13, 14 and 15.
6. An isolated polynucleotide encoding an antibody light chain comprising a VL of comprising SEQ ID NOs: 16, 17 and 18.
7. A vector comprising a polynucleotide encoding an antibody of claim 1 .
8. A vector comprising a polynucleotide encoding an antibody, wherein the HCDR1, the HCDR2 and the HCDR3 comprise the amino acid sequences of SEQ ID NOs: 13, 14 and 15, respectively, and the LCDR1, the LCDR2 and the LCDR3 comprise the amino acid sequences of SEQ ID NOs: 16, 17 and 18, respectively.
9. A vector comprising a polynucleotide encoding an antibody of claim 2 .
10. A host cell comprising the polynucleotide of claim 5 or 6 .
11. A host cell comprising the vector of claim 7 .
12. A host cell comprising the vector of claim 8 .
13. A host cell comprising the vector of claim 9 .
14. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.